Dr
Andrew
Wells

Partner & Head of Chemistry

Manchester Office

Chemistry

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 752 507 1499
Email. [email protected]

Experience

Andrew’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices. Outside of the pharmaceutical field, Andrew’s practice encompasses agrochemicals, polymer chemistry, petroleum additives, catalytic compositions, separation chemistry, adhesive technologies and biosensors.

Andrew acts for a diverse range of clients, including international corporations, universities, start-up companies and associate patent attorney firms based outside of the UK.

He commenced his patent career in private practice before joining the in-house patent department of a major multi-national pharmaceutical company in June 2004. As an in-house attorney, Andrew was responsible for the patent portfolios relating to a number of high priority drug development projects, as well as conducting IP due diligence evaluations to support in-licensing activities. Andrew returned to private practice in November 2008 when he joined the Manchester office of HGF as a Partner.

Andrew draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters, including patent portfolio management, enforcing patent rights, challenging third party patent rights, providing infringement and validity opinions, and conducting due diligence evaluations to support licensing and acquisition deals. Andrew also has considerable experience in representing clients in opposition and appeal proceedings at the European Patent Office.

Specialisms

  • Catalysis
  • Material science
  • Pharmaceutical technologies
  • Polymer chemistry

Industries

  • Agrochemicals icon Agrochemicals
  • Healthcare icon Healthcare
  • Medical devices icon Medical devices
  • Pharmaceuticals icon Pharmaceuticals

Services

  • Due diligence
  • In-house legal support
  • Patent oppositions & appeals
  • Patent term extensions & SPCs
  • Patents
  • Portfolio management
  • Searching & competitor monitoring
  • Strategy

Qualifications

Patent Attorney

Chartered (UK)
European


OTHER

BPharm

PHD

The development and evaluation of microparticulate formulations for DNA immunisation

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate in Intellectual Property Law

Recognition

IAM Strategy 300 - Leading IP Strategists

Andrew is listed in the IAM Strategy 300 as a leading IP strategist

View recognition online

IAM Patent 1000

Andrew is listed in the IAM Patent 1000 as a leading IP attorney in his field.

View recognition online

MIP Star

Andrew is listed as a MIP Star.

View recognition online

Publications

Drug repurposing: progress, challenges and recommendations - Nature Medicine article on Drug Repurposing

View publication online

CSR

Andrew mentors and contributes to the professional training of Trainee Patent Attorneys within HGF, as well as mentoring and training of IP and technology transfer professionals in other organisations.

Related News

EPO Enlarged Board of Appeal decision G4/19 - a European patent application can be refused by reason of the prohibition on double patenting

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can …

Read article

Managing Intellectual Property IP Stars & Firm Rankings 2021

Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …

Read article

Medical technology most patented subject matter at EPO in 2020

Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …

Read article

The EPO ‘How To’ guide for antibody applications in Europe

The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …

Read article

Personalised drug patenting in Europe

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …

Read article

The Internet of Medical Things

Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …

Read article

Covid-19 vaccine patent waivers

To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …

Read article

G1/21 hearing at the EPO

Follow this page for the updates from G1/21 hearing at the EPO on 28th May 2021. HGF Partners Dr Chris Moore and Douglas Drysdale will be reporting all the key …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.